Tumor Biology

, Volume 37, Issue 2, pp 2683–2690 | Cite as

FXR1 is elevated in colorectal cancer and acts as an oncogene

Original Article


Fragile X-related gene 1 (FXR1) is deregulated in a variety of human disorders including cancer. However, there is relatively little evidence concerning the relationship between FXR1 and colorectal cancer. Western blot, immunohistochemistry (IHC), and quantitative real-time PCR (qRT-PCR) were adopted to detect the FXR1 protein and messenger RNA (mRNA) expression, respectively. Enzyme-linked immunosorbent assay (ELISA) was used to evaluate the plasma FXR1 expression in our study. MTT assay and colony formation assay were used to examine the proliferation ability of cells in vitro. In addition, Transwell assays were performed to test the migration and invasion abilities of cancer cells. We found that the average plasma FXR1 level in CRC was significantly higher than that in healthy controls (P < 0.001). Moreover, the plasma expression of FXR1 in stage IV patients was dramatically higher than that in stage I, stage II, and stage III patients (P < 0.001). Consistently, FXR1 mRNA expression levels were much higher in cancer tissues than that in normal tissues. Moreover, IHC results showed that cancer tissues possessed higher FXR1 expression (P = 0.027). What’s more, plasma FXR1 was a risk factor of colorectal cancer indicated by univariate survival analysis (P = 0.021, HR = 1.685, 95 % CI 1.336–1.927). Multivariate analysis suggested that FXR1 was an independent risk factor of colorectal cancer (P = 0.008, HR = 1.381, 95 % CI 1.119–1.741). Kaplan-Meier analysis showed that the patients with higher plasma FXR1 expression had a poorer outcome (P < 0.001). Besides, FXR1 acted as an oncogene which could increase the proliferation, migration, and invasion of cancer cells. All these data indicate that FXR1 might act as a tumor promoter. Future investigations are warranted to explore whether FXR1 may represent a novel therapeutic target.


Colorectal cancer Fragile X-related gene 1 Prognosis Oncogene 



We thank Prof. Liu for technical support.

Conflicts of interest



  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Kirkpatrick LL, McIlwain KA, Nelson DL. Comparative genomic sequence analysis of the fxr gene family: Fmr1, fxr1, and fxr2. Genomics. 2001;78:169–77.CrossRefPubMedGoogle Scholar
  3. 3.
    Engels B, van 't Padje S, Blonden L, Severijnen LA, Oostra BA, Willemsen R. Characterization of fxr1 in danio rerio; a simple vertebrate model to study costamere development. J Exp Biol. 2004;207:3329–38.CrossRefPubMedGoogle Scholar
  4. 4.
    Tabrizi M, Khalili M, Vasei M, Nouraei N, Mansour Samaei N, Khavanin A, et al. Evaluating the mir-302b and mir-145 expression in formalin-fixed paraffin-embedded samples of esophageal squamous cell carcinoma. Arch Iran Med. 2015;18:173–8.PubMedGoogle Scholar
  5. 5.
    Kumar P, Rawat A, Keshari AK, Singh AK, Maity S, De A, et al. Antiproliferative effect of isolated isoquinoline alkaloid from mucuna pruriens seeds in hepatic carcinoma cells. Nat Prod Res. 2015;16:1–4.Google Scholar
  6. 6.
    Kang MH, Moon SU, Sung JH, Kim JW, Lee KW, Lee HS, Lee JS, Kim JH. Antitumor activity of hm781-36b, alone or in combination with chemotherapeutic agents, in colorectal cancer cells. Cancer Res Treat. 2015Google Scholar
  7. 7.
    Davidovic L, Durand N, Khalfallah O, Tabet R, Barbry P, Mari B, et al. A novel role for the rna-binding protein fxr1p in myoblasts cell-cycle progression by modulating p21/cdkn1a/cip1/waf1 mrna stability. PLoS Genet. 2013;9:e1003367.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Garnon J, Lachance C, Di Marco S, Hel Z, Marion D, Ruiz MC, et al. Fragile x-related protein fxr1p regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem. 2005;280:5750–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, et al. Regulation of synaptic structure and function by fmrp-associated micrornas mir-125b and mir-132. Neuron. 2010;65:373–84.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kirkpatrick LL, McIlwain KA, Nelson DL. Alternative splicing in the murine and human fxr1 genes. Genomics. 1999;59:193–202.CrossRefPubMedGoogle Scholar
  11. 11.
    Mientjes EJ, Willemsen R, Kirkpatrick LL, Nieuwenhuizen IM, Hoogeveen-Westerveld M, Verweij M, et al. Fxr1 knockout mice show a striated muscle phenotype: implications for fxr1p function in vivo. Hum Mol Genet. 2004;13:1291–302.CrossRefPubMedGoogle Scholar
  12. 12.
    Khandjian EW, Bardoni B, Corbin F, Sittler A, Giroux S, Heitz D, et al. Novel isoforms of the fragile x related protein fxr1p are expressed during myogenesis. Hum Mol Genet. 1998;7:2121–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Huot ME, Bisson N, Davidovic L, Mazroui R, Labelle Y, Moss T, et al. The rna-binding protein fragile x-related 1 regulates somite formation in xenopus laevis. Mol Biol Cell. 2005;16:4350–61.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Van't Padje S, Chaudhry B, Severijnen LA, van der Linde HC, Mientjes EJ, Oostra BA, et al. Reduction in fragile x related 1 protein causes cardiomyopathy and muscular dystrophy in zebrafish. J Exp Biol. 2009;212:2564–70.CrossRefGoogle Scholar
  15. 15.
    Davidovic L, Sacconi S, Bechara EG, Delplace S, Allegra M, Desnuelle C, et al. Alteration of expression of muscle specific isoforms of the fragile x related protein 1 (fxr1p) in facioscapulohumeral muscular dystrophy patients. J Med Genet. 2008;45:679–85.CrossRefPubMedGoogle Scholar
  16. 16.
    Oldenburg AR, Delbarre E, Thiede B, Vigouroux C, Collas P. Deregulation of fragile x-related protein 1 by the lipodystrophic lamin a p.R482w mutation elicits a myogenic gene expression program in preadipocytes. Hum Mol Genet. 2014;23:1151–62.CrossRefPubMedGoogle Scholar
  17. 17.
    Cook D, Sanchez-Carbente Mdel R, Lachance C, Radzioch D, Tremblay S, Khandjian EW, et al. Fragile x related protein 1 clusters with ribosomes and messenger rnas at a subset of dendritic spines in the mouse hippocampus. PLoS One. 2011;6:e26120.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Bolivar J, Guelman S, Iglesias C, Ortiz M, Valdivia MM. The fragile-x-related gene fxr1 is a human autoantigen processed during apoptosis. J Biol Chem. 1998;273:17122–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Xu XL, Zong R, Li Z, Biswas MH, Fang Z, Nelson DL, et al. Fxr1p but not fmrp regulates the levels of mammalian brain-specific microrna-9 and microrna-124. J Neurosci. 2011;31:13705–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Vasudevan S, Steitz JA. Au-rich-element-mediated upregulation of translation by fxr1 and argonaute 2. Cell. 2007;128:1105–18.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007;318:1931–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Qian J, Hassanein M, Hoeksema MD, Harris BK, Zou Y, Chen H, et al. The rna binding protein fxr1 is a new driver in the 3q26-29 amplicon and predicts poor prognosis in human cancers. Proc Natl Acad Sci U S A. 2015;112:3469–74.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang J, Qian J, Hoeksema MD, Zou Y, Espinosa AV, Rahman SM, et al. Integrative genomics analysis identifies candidate drivers at 3q26-29 amplicon in squamous cell carcinoma of the lung. Clin Cancer Res. 2013;19:5580–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Comtesse N, Keller A, Diesinger I, Bauer C, Kayser K, Huwer H, et al. Frequent overexpression of the genes fxr1, clapm1 and eif4g located on amplicon 3q26-27 in squamous cell carcinoma of the lung. Int J Cancer. 2007;120:2538–44.CrossRefPubMedGoogle Scholar
  25. 25.
    Fields AP, Justilien V. The guanine nucleotide exchange factor (gef) ect2 is an oncogene in human cancer. Adv Enzyme Regul. 2010;50:190–200.CrossRefPubMedGoogle Scholar
  26. 26.
    Fields AP, Regala RP. Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res. 2007;55:487–97.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ma Y, Wang C, Li B, Qin L, Su J, Yang M, et al. Bcl-2-associated transcription factor 1 interacts with fragile x-related protein 1. Acta Biochim Biophys Sin (Shanghai). 2014;46:119–27.CrossRefGoogle Scholar
  28. 28.
    Lejeune FJ, Ruegg C, Lienard D. Clinical applications of tnf-alpha in cancer. Curr Opin Immunol. 1998;10:573–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357:539–45.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of General Surgerythe Fourth Affiliated Hospital of Harbin Medical UniversityHarbinPeople’s Republic of China
  2. 2.Section Three, Orthopedic Surgery Departmentthe Fifth Hospital of HarbinHarbinPeople’s Republic of China

Personalised recommendations